For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Tissue biology

ARA-290 research peptide

ARA-290 is cibinetide, an eleven-residue peptide named for the helix B surface of erythropoietin and studied as an agonist of the innate repair receptor.

2 sizes · from $19.99 · 2 in stock · flat $24.95 US shipping per order

Sizes, prices and availability

ARA-290 sizes and prices
SizeSKUStated purityBatch COAPriceAvailability
10 mg PP-ARA290-10MG Not yet provided Not yet provided $19.99 In stock
20 mg PP-ARA290-20MG Not yet provided Not yet provided $36.99 In stock

Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details

About ARA-290

ARA-290 is cibinetide, also called pyroglutamate helix B surface peptide (pHBSP). It is an eleven-residue peptide, pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, that is studied as an agonist of the innate repair receptor (IRR), a heteromer of the erythropoietin receptor and the beta common receptor (Bitto et al., 2018; Dennhardt et al., 2022).

Bitto et al. (2018) report that cibinetide improved impaired wound healing in diabetic mice and that the effect involved activation of the EPOR-beta common receptor complex. Nairz et al. (2017) report that it dampened innate immune cell functions in experimental colitis. Culver et al. (2017) report a 28-day, randomised phase 2b trial in 64 subjects with sarcoidosis-associated small nerve fibre loss, which used corneal nerve fibre area as the primary surrogate endpoint. The clinical work describes a trial design and endpoints and is not a claim about this research material.

What the published literature covers

  • Bitto et al. (2018) examine cibinetide in a diabetic mouse wound-healing model.
  • Nairz et al. (2017) report effects of cibinetide on innate immune cells in experimental colitis.
  • Culver et al. (2017) report a phase 2b trial in sarcoidosis-associated small nerve fibre loss.
  • Dennhardt et al. (2022) examine IRR targeting by erythropoietin or pHBSP in a mouse model.

Vial arithmetic

The peptide reconstitution calculator converts a vial size, diluent volume and target amount into concentration, syringe units and draws per vial. Volumes convert to syringe units with the syringe units converter. It does arithmetic only and does not suggest any amount.

FAQ

Is ARA-290 the same as cibinetide?

Yes. PubChem lists ARA-290 and ARA290 as synonyms of cibinetide (CID 91810664, C51H84N16O21, 1257.3 g/mol), also called pHBSP.

What receptor is ARA-290 studied at?

The innate repair receptor, a complex of the erythropoietin receptor and the beta common receptor (Bitto et al., 2018).

What sizes of ARA-290 does Covalume list?

Covalume lists ARA-290 in 2 sizes: 10 mg, 20 mg. Each size shows its price and live stock status in the variants table on this page.

How is the purity of ARA-290 documented?

Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.

References

  1. Bitto A, Irrera N, Pizzino G, et al. (2018). Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochim Biophys Acta Mol Basis Dis 1864:632-639. PubMed 29223734 · DOI
  2. Nairz M, Haschka D, Dichtl S, et al. (2017). Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep 7:13012. PubMed 29026145 · DOI
  3. Culver DA, Dahan A, Bajorunas D, et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci 58:BIO52-BIO60. PubMed 28475703 · DOI
  4. Dennhardt S, Pirschel W, Wissuwa B, et al. (2022). Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice. Front Immunol 13:1010882. PubMed 36211426 · DOI

Identity values are from PubChem (CID 91810664) and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-18.

Related research peptides

From the research library